Business
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.","length":401,"tagName":"p"},{"type":"image","alt":"Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Pingsheng Hu (left), Chairman and General Manager of Sinorda Biomedicine, signed the partnership agreement","displaySize":"","headline":null,"caption":"Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Pingsheng Hu (left), Chairman and General Manager of Sinorda Biomedicine, signed the partnership agreement","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":247,"url":"https://media.zenfs.com/en/prnewswire.com/052add0a07373ad936f3bdfeb10f4523"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U12vxQlFb8jY9P0aBlfi8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQzNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/052add0a07373ad936f3bdfeb10f4523","width":400,"height":247}},"href":"https://mma.prnewswire.com/media/2872253/Dr_Chris_Chen__right__CEO_WuXi_Biologics_Dr_Pingsheng_Hu.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, Sinorda Biomedicine will leverage WuXi Biologics' extensive experience and manufacturing capabilities in biologics development and manufacturing to advance SND006's preclinical pharmacology studies and clinical supply, accelerating the Investigational New Drug (IND) application process. SND006 is an innovative bispecific antibody independently developed by Sinorda Biomedicine, for which the company holds worldwide rights. Sinorda Biomedicine has completed in vitro functional validation studies of SND006 and plans to submit IND applications to both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in 2026. In the future, the two companies will further expand their collaboration around Sinorda Biomedicine's potential pipeline, including multiple integrated projects spanning from molecule discovery to clinical manufacturing.","length":925,"tagName":"p"},{"type":"text"...